Morgan Stanley’s price target indicates a potential upside of 16.48% from the stock’s current price. Evercore reiterated an “outperform” rating and set a $200.00 target price on shares of Guardant Health in a research report on Monday, July 6th. Get Guardant Health alerts:Check Out Our Latest Analysis on GHGuardant Health Trading Down 2.0%Insider Buying and SellingShares of GH opened at $158.83 on Tuesday. In other Guardant Health news, CFO Michael Brian Bell sold 2,000 shares of Guardant Health stock in a transaction that occurred on Friday, June 5th. See AlsoReceive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.